{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:10:34Z","timestamp":1785168634141,"version":"3.55.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2465,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>Acute renal failure (ARF), recently renamed acute kidney injury (AKI), is a relatively frequent problem, occurring in approximately 20% of hospitalized patients with cirrhosis. Although serum creatinine may underestimate the degree of renal dysfunction in cirrhosis, measures to diagnose and treat AKI should be made in patients in whom serum creatinine rises abruptly by 0.3 mg\/dL or more (\u226526.4 \u03bcmol\/L) or increases by 150% or more (1.5-fold) from baseline. The most common causes of ARF (the term is used interchangeably with AKI) in cirrhosis are prerenal azotemia (volume-responsive prerenal AKI), acute tubular necrosis, and hepatorenal syndrome (HRS), a functional type of prerenal AKI exclusive of cirrhosis that does not respond to volume repletion. Because of the progressive vasodilatory state of cirrhosis that leads to relative hypovolemia and decreased renal blood flow, patients with decompensated cirrhosis are very susceptible to developing AKI with events associated with a decrease in effective arterial blood volume. HRS can occur spontaneously but is more frequently precipitated by events that worsen vasodilatation, such as spontaneous bacterial peritonitis.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Specific therapies of AKI depend on the most likely cause and mechanism. Vasoconstrictors are useful bridging therapies in HRS. Ultimately, liver transplantation is indicated in otherwise reasonable candidates in whom AKI does not resolve with specific therapy. (Hepatology 2008;48:2064-2077.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22605","type":"journal-article","created":{"date-parts":[[2008,9,2]],"date-time":"2008-09-02T15:30:18Z","timestamp":1220369418000},"page":"2064-2077","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":547,"title":["Acute kidney injury in cirrhosis"],"prefix":"10.1097","volume":"48","author":[{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-35-20241201","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.","volume":"44","author":"DAmico","year":"2006","journal-title":"J Hepatol"},{"key":"R2-35-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2003.50016","article-title":"Model for endstage liver disease (MELD) and allocation of donor livers.","volume":"124","author":"Wiesner","year":"2003","journal-title":"Gastroenterology"},{"key":"R3-35-20241201","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/00365520801932944","article-title":"Prediction of survival after liver transplantation by pretransplant parameters.","volume":"43","author":"Weismuller","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"R4-35-20241201","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2008-1040323","article-title":"Pathogenesis and treatment of hepatorenal syndrome.","volume":"28","author":"Arroyo","year":"2008","journal-title":"Semin Liver Dis"},{"issue":"Suppl 1","key":"R5-35-20241201","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.jhep.2008.01.010","article-title":"Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.","volume":"48","author":"Angeli","year":"2008","journal-title":"J Hepatol"},{"key":"R6-35-20241201","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.mcna.2008.03.007","article-title":"The hepatorenal syndrome.","volume":"92","author":"Munoz","year":"2008","journal-title":"Med Clin North Am"},{"key":"R7-35-20241201","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bpg.2006.10.004","article-title":"Diagnosis and treatment of acute renal failure in patients with cirrhosis.","volume":"21","author":"Moreau","year":"2007","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R8-35-20241201","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.3748\/wjg.v13.i42.5552","article-title":"Acute renal dysfunction in liver diseases.","volume":"13","author":"Betrosian","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R9-35-20241201","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"R10-35-20241201","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9343(70)80073-0","article-title":"Renal failure in the patient with cirrhosis: the role of active vasoconstriction.","volume":"49","author":"Epstein","year":"1970","journal-title":"Am J Med"},{"key":"R11-35-20241201","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.","volume":"8","author":"Schrier","year":"1988","journal-title":"HEPATOLOGY"},{"key":"R12-35-20241201","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.","volume":"43","author":"Iwakiri","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R13-35-20241201","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"R14-35-20241201","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis.","volume":"42","author":"RuizdelArbol","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R15-35-20241201","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.","volume":"41","author":"Alessandria","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R16-35-20241201","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.","volume":"23","author":"Arroyo","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R17-35-20241201","first-page":"1310","article-title":"Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club.","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"R18-35-20241201","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/j.1572-0241.2001.03958.x","article-title":"Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis.","volume":"96","author":"Hampel","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R19-35-20241201","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1111\/j.1572-0241.2005.00271.x","article-title":"Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.","volume":"100","author":"Peron","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R20-35-20241201","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1053\/j.gastro.2005.09.024","article-title":"Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score.","volume":"129","author":"Terra","year":"2005","journal-title":"Gastroenterology"},{"key":"R21-35-20241201","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00134-005-2842-7","article-title":"The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis.","volume":"31","author":"du Cheyron","year":"2005","journal-title":"Intensive Care Med"},{"key":"R22-35-20241201","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5414\/CNP65028","article-title":"Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis.","volume":"65","author":"Wu","year":"2006","journal-title":"Clin Nephrol"},{"key":"R23-35-20241201","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type I heparorenal syndrome: a retrospective multicenter study.","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"R24-35-20241201","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/ndt\/gfm914","article-title":"Outcome predictors and new score of critically ill cirrhotic patients with acute renal failure.","volume":"23","author":"Fang","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R25-35-20241201","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-144-10-200605160-00007","article-title":"Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.","volume":"144","author":"McGuire","year":"2006","journal-title":"Ann Intern Med"},{"key":"R26-35-20241201","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0016-5085(98)70551-7","article-title":"Further evidence against the use of aminoglycosides in cirrhotic patients.","volume":"114","author":"GarciaTsao","year":"1998","journal-title":"Gastroenterology"},{"key":"R27-35-20241201","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI102813","article-title":"The cardiac output at rest in Laennecs cirrhosis.","volume":"32","author":"Kowalski","year":"1953","journal-title":"J Clin Invest"},{"key":"R28-35-20241201","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/00365517709100657","article-title":"Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function.","volume":"37","author":"RingLarsen","year":"1977","journal-title":"Scand J Clin Lab Invest"},{"key":"R29-35-20241201","first-page":"255","article-title":"Renal hemodynamic alterations in liver disease.","volume":"3","author":"Cohn","year":"1976","journal-title":"Perspect Nephrol Hypertens"},{"key":"R30-35-20241201","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2007.10.055","article-title":"Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis.","volume":"134","author":"Stadlbauer","year":"2008","journal-title":"Gastroenterology"},{"key":"R31-35-20241201","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0272-6386(82)80096-6","article-title":"Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study.","volume":"2","author":"Mandal","year":"1982","journal-title":"Am J Kidney Dis"},{"key":"R32-35-20241201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/hep.1840050229","article-title":"Tubular dysfunction in the deeply jaundiced patient with hepatorenal syndrome.","volume":"5","author":"Rector","year":"1985","journal-title":"HEPATOLOGY"},{"key":"R33-35-20241201","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.","volume":"29","author":"Angeli","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R34-35-20241201","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1046\/j.1523-1755.1998.00210.x","article-title":"Treatment of acute renal failure.","volume":"54","author":"Star","year":"1998","journal-title":"Kidney Int"},{"key":"R35-35-20241201","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0272-6386(86)80107-X","article-title":"Limitations of creatinine in quantifying the severity of cyclosporineinduced chronic nephropathy.","volume":"8","author":"Tomlanovich","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"R36-35-20241201","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1046\/j.1523-1755.2002.00149.x","article-title":"Molecular and structural consequences of early renal allograft injury.","volume":"61","author":"Baboolal","year":"2002","journal-title":"Kidney Int"},{"key":"R37-35-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1258\/acb.2007.007079","article-title":"Extent of bilirubin interference with Beckman creatinine methods.","volume":"45","author":"Dimeski","year":"2008","journal-title":"Ann Clin Biochem"},{"key":"R38-35-20241201","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1365-2036.2007.03443.x","article-title":"Review article: renal function assessment in cirrhosisdifficulties and alternative measurements.","volume":"26","author":"Cholongitas","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R39-35-20241201","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Longterm therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine.","volume":"30","author":"Gulberg","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R40-35-20241201","first-page":"15","article-title":"Longterm terlipressin administration improves renal function in cirrhotic patients with type I hepatorenal syndrome: a pilot study.","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"R41-35-20241201","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","article-title":"Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.","volume":"17","author":"Colle","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R42-35-20241201","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","article-title":"Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.","volume":"14","author":"Halimi","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R43-35-20241201","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.","volume":"36","author":"Duvoux","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R44-35-20241201","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebocontrolled clinical trial.","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R45-35-20241201","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ndt\/gfh930","article-title":"Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.","volume":"20","author":"Kiser","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R46-35-20241201","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R47-35-20241201","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, doubleblind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"R48-35-20241201","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.","volume":"134","author":"MartinLlahi","year":"2008","journal-title":"Gastroenterology"},{"key":"R49-35-20241201","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/hep.1840060216","article-title":"Hepatorenal syndrome without avid sodium retention.","volume":"6","author":"Dudley","year":"1986","journal-title":"HEPATOLOGY"},{"key":"R50-35-20241201","doi-asserted-by":"crossref","first-page":"597","DOI":"10.7326\/0003-4819-96-5-597","article-title":"Nonoliguric acute renal failure associated with a low fractional excretion of sodium.","volume":"96","author":"Diamond","year":"1982","journal-title":"Ann Intern Med"},{"key":"R51-35-20241201","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.2.5920.670-b","article-title":"Letter: renal disorders in hepatic failure.","volume":"2","author":"Eknoyan","year":"1974","journal-title":"Br Med J"},{"key":"R52-35-20241201","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/archinte.1937.00180060081008","article-title":"Renal function in obstructive jaundice.","volume":"60","author":"Elsom","year":"1937","journal-title":"Arch Intern Med"},{"key":"R53-35-20241201","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.ajkd.2003.10.040","article-title":"Urinary interleukin18 is a marker of human acute tubular necrosis.","volume":"43","author":"Parikh","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R54-35-20241201","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.21901","article-title":"Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.","volume":"46","author":"Krag","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R55-35-20241201","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0016-5085(87)90327-1","article-title":"Effects of renal impairment on liver transplantation.","volume":"93","author":"Rimola","year":"1987","journal-title":"Gastroenterology"},{"key":"R56-35-20241201","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pretransplant renal function on survival after liver transplantation.","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"R57-35-20241201","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/jhep.2002.33160","article-title":"Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.","volume":"35","author":"Nair","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R58-35-20241201","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1111\/j.1600-6143.2006.01526.x","article-title":"Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?","volume":"6","author":"Gonwa","year":"2006","journal-title":"Am J Transplant"},{"key":"R59-35-20241201","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/lt.20617","article-title":"Impact of pretransplant renal failure: when is listing for kidneyliver indicated?","volume":"11","author":"Davis","year":"2005","journal-title":"Liver Transpl"},{"key":"R60-35-20241201","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a casecontrol study.","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"},{"key":"R61-35-20241201","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1600-6143.2007.01856.x","article-title":"Simultaneous liverkidney transplantation: evaluation to decision making.","volume":"7","author":"Davis","year":"2007","journal-title":"Am J Transplant"},{"key":"R62-35-20241201","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/lt.20017","article-title":"Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations.","volume":"10","author":"Gonwa","year":"2004","journal-title":"Liver Transpl"},{"key":"R63-35-20241201","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.","volume":"36","author":"Ortega","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R64-35-20241201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.","volume":"33","author":"Uriz","year":"2001","journal-title":"J Hepatol"},{"key":"R65-35-20241201","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.","volume":"40","author":"Wong","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R66-35-20241201","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"OctreotideMidodrine therapy significantly improves renal function and 30day survival in patients with type 1 hepatorenal syndrome.","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R67-35-20241201","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, doubleblind, placebocontrolled, crossover study.","volume":"38","author":"PomierLayrargues","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R68-35-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/gast.2001.22529","article-title":"Octreotide potentiates PKCdependent vasoconstrictors in portalhypertensive and control rats.","volume":"120","author":"Wiest","year":"2000","journal-title":"Gastroenterology"},{"key":"R69-35-20241201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.","volume":"27","author":"Guevara","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R70-35-20241201","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome.","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"key":"R71-35-20241201","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2008.03.034","article-title":"Vasoconstrictor therapy for the hepatorenal syndrome.","volume":"134","author":"Lim","year":"2008","journal-title":"Gastroenterology"},{"key":"R72-35-20241201","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"R73-35-20241201","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R74-35-20241201","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","article-title":"Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.","volume":"28","author":"Guevara","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R75-35-20241201","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.47.2.288","article-title":"Longterm outcome after transjugular intrahepatic portosystemic stentshunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study.","volume":"47","author":"Brensing","year":"2000","journal-title":"Gut"},{"key":"R76-35-20241201","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1080\/003655200750023642","article-title":"Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure.","volume":"35","author":"Michl","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"R77-35-20241201","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/lv.2000.6355","article-title":"Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial.","volume":"6","author":"Mitzner","year":"2000","journal-title":"Liver Transpl"},{"issue":"Suppl 1","key":"R78-35-20241201","first-page":"564A","article-title":"Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 hrs enrolled in a randomized, doubleblind,placebocontrolled trial. Abstract.","volume":"46","author":"Sanyal","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R79-35-20241201","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","article-title":"Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.","volume":"94","author":"Gines","year":"1988","journal-title":"Gastroenterology"},{"key":"R80-35-20241201","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/gast.1997.v113.pm9247479","article-title":"Paracentesisinduced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis.","volume":"113","author":"Ruiz del Arbol","year":"1997","journal-title":"Gastroenterology"},{"key":"R81-35-20241201","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0016-5085(96)70068-9","article-title":"Randomized trial comparing albumin, dextran70 and polygeline in cirrhotic patients with ascites treated by paracentesis.","volume":"111","author":"Gines","year":"1996","journal-title":"Gastroenterology"},{"key":"R82-35-20241201","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R83-35-20241201","first-page":"441A","article-title":"Serum creatinine and bilirubin levels at admission are useful to select patients with SBP who should be treated with plasma expansion with albumin. Abstract.","volume":"44","author":"Terg","year":"2006","journal-title":"HEPATOLOGY"},{"issue":"Suppl 1","key":"R84-35-20241201","doi-asserted-by":"crossref","first-page":"S91A","DOI":"10.1016\/S0168-8278(07)61818-2","article-title":"Intravenous albumin is not necessary in cirrhotic patients with spontaneous bacterial peritonitis and lowrisk of mortality. Abstract.","volume":"46","author":"Casas","year":"2007","journal-title":"J Hepatol"},{"key":"R85-35-20241201","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.","volume":"133","author":"Fernandez","year":"2007","journal-title":"Gastroenterology"},{"key":"R86-35-20241201","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2008-1040319","article-title":"Bacterial infections, sepsis, and multiorgan failure in cirrhosis.","volume":"28","author":"Tandon","year":"2008","journal-title":"Semin Liver Dis"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22605","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200812000-00035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:36:42Z","timestamp":1733060202000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200812000-00035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22605","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}